Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). This study retrospectively analyzed the outcomes of...

Full description

Bibliographic Details
Main Authors: Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, Tina Czaplinska, Gillian Sanchez, Claudia Brady, Marina Kremyanskaya, Michal Bar-Natan, Alla Keyzner, Bridget K. Marcellino, Janice Gabrilove, Shyamala C. Navada, Lewis R. Silverman, Siraj M. El Jamal, John Mascarenhas, Alan H. Shih
Format: Article
Language:English
Published: Wolters Kluwer 2021-04-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000549

Internet

http://journals.lww.com/10.1097/HS9.0000000000000549

Similar Items